1.MicroRNA and human cancer
Changzhen REN ; Huan CHEN ; Binghua JIAO
Journal of International Oncology 2011;38(9):649-652
MicroRNA (miRNA) is a family of endogenous,non-coding small RNAs molecules that function as gene regulators.It has been revealed that miRNAs may play a critical role in many biological processes including cell proliferation,differentiation and apoptosis.Recent studies demonstrate that aberrant expression of miRNAs can lead to several human diseases even cancer.These tiny but potent molecules have the function as anti-oncogene or oncogene.Accordingly,further study of miRNAs has opened a novel avenue in the diagnosis and treatment of human cancer.
2.Overexpression of the tumor suppressor gene PTEN inhibits the phosphorylation of Akt in activated hepatic stellate cells in vitro
Lisen HAO ; Xiaolan ZHANG ; Changzhen REN ; Liwen LI ; Jing WANG ; Yanbo MO ; Rongrong BIAN ; Yue WEI ; Jiaqi ZHANG ; Yuling LIU
The Journal of Practical Medicine 2014;(7):1069-1072
Objective Using an adenoviral vector , the wild-type PTEN gene was transduced into activated hepatic stellate cell (HSC) in vitro and the phosphorylation status of Akt were investigated. Methods The wild type PTEN gene was transduced into activated HSC in vitro mediated by adenoviral vector. The expressions of PTEN and total Akt in HSC were measured by Western blot and Real-time fluorescent quantitation PCR. And the expressions of phosphorylated Akt (Thr308) in HSC was determined by Western blot. Results The data showed that exogenous wild type PTEN gene was successfully transduced and expressed in activated HSC in vitro. The over-expression of wild type PTEN resulted in the significant down-regulated expression of phosphorylated Akt (Thr308) in activated HSC (P < 0.01). But no significant defferences were found in the expression of total Akt in activated HSC at both transcriptional and translational levels(P>0.50). Conclusions The overexpression of wild-type PTEN can negatively regulate PI3K/Akt signaling transduction by inhibiting the phosphorylation of Akt in activated HSC in vitro.
3.Primary skull base chondrosarcoma: a clinicopathological analysis
Yu ZHANG ; Xiangna CHEN ; Caihong REN ; Changzhen JIANG ; Yupeng CHEN ; Na LIN ; Mi WANG ; Shanshan CAI ; Guoping LI ; Sheng ZHANG ; Xingfu WANG
Chinese Journal of Pathology 2020;49(3):239-243
Objective:To investigate the clinicopathological features, immunophenotype, molecular characteristics and differential diagnosis of primary skull base chondrosarcoma.Methods:Nine cases of primary skull base chondrosarcoma were collected at the First Affiliated Hospital of Fujian Medical University, from January 2006 to June 2019, reviewed for the clinical and radiologic data and morphologic features, immunophenotype and molecular characteristics.Results:Among all the 9 cases, six were male, three were frmale, with average age 47 years, and median age 47 years; five cases were WHO gradeⅠ, and four were WHO grade Ⅱ. Microscopically, the tumor showed lobulated growth pattern with low-medium cellularity within a chondroid or mucoid background. The tumor cells showed mild-moderate atypia, with binucleated forms, and mitosis was rare or occasional. Immunohistochemistry (IHC) showed tumor cells were positive for S-100 protein, vimentin, SOX-9 and D2-40, and negative for Brachyury, CK, EMA and CK8/18; the Ki-67 index was low (1% to 5%). Molecular analysis showed IDH1 R132C mutation in four cases.Conclusions:Skull base chondrosarcoma is a rare cartilaginous malignant tumor with a good prognosis. Its characteristic morphologies, combined with IHC and molecular detection are helpful for the differential diagnosis.